QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:ISEE

IVERIC bio (ISEE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$39.95
$39.95
50-Day Range
$36.90
$39.95
52-Week Range
$9.39
$39.99
Volume
N/A
Average Volume
3.62 million shs
Market Capitalization
$5.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.75

IVERIC bio MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
35.5% Downside
$25.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$789,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.77) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.70 out of 5 stars

Medical Sector

959th out of 961 stocks

Biotechnology Industry

12th out of 13 stocks


ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.


ISEE Stock News Headlines

Astellas Completes Acquisition of Iveric Bio
B.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Iveric bio, Still A 5+% Opportunity
IVERIC Bio (NASDAQ: ISEE)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Check Out What Whales Are Doing With ISEE
Astellas Pharma To Acquire Iveric Bio In $5.9 Bln Deal
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
3/01/2023
Today
9/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.75
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
-35.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$-185,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.43 per share

Miscellaneous

Free Float
134,063,000
Market Cap
$5.50 billion
Optionable
Optionable
Beta
1.06
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Glenn P. Sblendorio M.B.A. (Age 67)
    CEO & Director
    Comp: $1.36M
  • Dr. Pravin U. Dugel M.D. (Age 59)
    Pres & Director
    Comp: $984.82k
  • Mr. David F. Carroll M.B.A. (Age 57)
    Sr. VP, CFO & Treasurer
    Comp: $725.55k
  • Mr. Keith Westby M.B.A.Mr. Keith Westby M.B.A. (Age 48)
    Sr. VP & COO
    Comp: $701.68k
  • Mr. Christopher Paul SimmsMr. Christopher Paul Simms (Age 48)
    Sr. VP & Chief Commercial Officer
    Comp: $715.01k
  • Dr. Samir C. Patel (Age 62)
    Co-Founder and Consultant
  • Dr. Xiao-Ping Dai Ph.D.
    Chief Technical Officer
  • Ms. Kathy Galante
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Todd D.C. Anderman
    Sr. VP, Chief Legal Officer & Corp. Sec.
  • Ms. Amy R. Sheehan
    Sr. VP & Chief HR Officer













ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2023?

10 brokers have issued 1-year target prices for IVERIC bio's stock. Their ISEE share price forecasts range from $19.00 to $35.00. On average, they predict the company's stock price to reach $25.75 in the next twelve months. This suggests that the stock has a possible downside of 35.5%.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) released its quarterly earnings data on Wednesday, March, 1st. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the business posted ($0.29) EPS.

What ETFs hold IVERIC bio's stock?

ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB), AltShares Event-Driven ET (EVNT) and Vanguard Russell 2000 Growth ETF (VTWG).Vanguard Russell 2000 ETF (VTWO).

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (3.40%), TCG Crossover Management LLC (1.78%), Nuveen Asset Management LLC (0.74%), Segantii Capital Management Ltd (0.64%), Picton Mahoney Asset Management (0.00%) and Marshall Wace LLP (0.44%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $39.95.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $5.50 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does IVERIC bio have?

The company employs 163 workers across the globe.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -